Talk:HLA-G

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia

This article was the subject of a Wiki Education Foundation-supported course assignment, between 5 January 2022 and 11 March 2022. Further details are available on the course page. Student editor(s): Immcarle183 (article contribs).

Suggestion: to add a section on HLA-G as a therapeutic target[edit]

disclaimer:

I'm new here, so I didn't want to edit the main page directly. I also hold a patent on HLA-G-based therapeutics (for use in autoimmune diseases), but are not associated with the companies/projects that are further developed and which I would thus suggest to add here (use as target in cancer therapy)

TTX-080 is a therapeutic antibody developed by Tizona and Gilead for cancer therapy which blocks the interaction of HLA-G and immunossuppressive receptors https://jitc.bmj.com/content/8/Suppl_3/A419.2 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278316/

Invectys is developing CAR-T cells that target HLA-G https://jitc.bmj.com/content/jitc/9/3/e001998.full.pdf?with-ds=yes — Preceding unsigned comment added by Vbruttel (talkcontribs) 20:27, 29 September 2023 (UTC)[reply]

Untitled[edit]

I'm making the following bibliography

Bibliography[edit]

  • Loustau. (2020). HLA-G Neo-Expression on Tumors. Frontiers in Immunology., 11. https://doi.org/10.3389/fimmu.2020.01685.[1]
    • This article lists the possible uses of HLA-G as a target for immunotherapies, as the protein is often expressed on cancerous cells. Fronteirs in Immunology is a high impact journal, so this is probably important information.
  •   Sabbagh. (2018). The role of HLA-G in parasitic diseases. HLA : Immune Response Genetics., 91(4), 255–270. https://doi.org/10.1111/tan.13196.[2]
    • This article is about HLA-G's role in terms of combating infectious diseases. This is a good article to add to the bibliography because there are many sources about cancer, but this one was unique in its focus.
  • Attia, J. V. D., Dessens, C. E., Van De Water, R., Houvast, R. D., Kuppen, P. J. K., & Krijgsman, D.. (2020). The Molecular and Functional Characteristics of HLA-G and the Interaction with Its Receptors: Where to Intervene for Cancer Immunotherapy?. International Journal of Molecular Sciences, 21(22), 8678. https://doi.org/10.3390/ijms21228678.[3]
    • This article focuses in on the structure of HLA-G and how that might affect its function.
  •   Li. (2021). HLA-G/sHLA-G and HLA-G-Bearing Extracellular Vesicles in Cancers: Potential Role as Biomarkers. Frontiers in Immunology., 12. https://doi.org/10.3389/fimmu.2021.791535.[4]
    • This recent review discusses possible ways to use HLA-G as a biomarker to test for cancer.

--Immcarle183 (talk) 06:58, 26 January 2022 (UTC)[reply]

References

  1. ^ Loustau, Maria; Anna, François; Dréan, Raphaelle; Lecomte, Martin; Langlade-Demoyen, Pierre; Caumartin, Julien (2020). "HLA-G Neo-Expression on Tumors". Frontiers in Immunology. 11. doi:10.3389/fimmu.2020.01685. ISSN 1664-3224. PMC 7456902. PMID 32922387.{{cite journal}}: CS1 maint: PMC format (link) CS1 maint: unflagged free DOI (link)
  2. ^ Sabbagh, A.; Sonon, P.; Sadissou, I.; Mendes-Junior, C. T.; Garcia, A.; Donadi, E. A.; Courtin, D. (2018). "The role of HLA-G in parasitic diseases". HLA. 91 (4): 255–270. doi:10.1111/tan.13196. ISSN 2059-2310.
  3. ^ Attia, Jiji V. D.; Dessens, Charlotte E.; van de Water, Ricky; Houvast, Ruben D.; Kuppen, Peter J. K.; Krijgsman, Daniëlle (2020-01). "The Molecular and Functional Characteristics of HLA-G and the Interaction with Its Receptors: Where to Intervene for Cancer Immunotherapy?". International Journal of Molecular Sciences. 21 (22): 8678. doi:10.3390/ijms21228678. PMC 7698525. PMID 33213057. {{cite journal}}: Check date values in: |date= (help)CS1 maint: PMC format (link) CS1 maint: unflagged free DOI (link)
  4. ^ Li, Peilong; Wang, Nan; Zhang, Yi; Wang, Chuanxin; Du, Lutao (2021). "HLA-G/sHLA-G and HLA-G-Bearing Extracellular Vesicles in Cancers: Potential Role as Biomarkers". Frontiers in Immunology. 12. doi:10.3389/fimmu.2021.791535. ISSN 1664-3224. PMC 8636042. PMID 34868081.{{cite journal}}: CS1 maint: PMC format (link) CS1 maint: unflagged free DOI (link)